{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-07T15:30:08.139003+00:00","company":{"ticker":"LMAT","cik":1158895,"company_name":"LEMAITRE VASCULAR INC"},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"shareholder_vote","fact_key":"7d0ae3e8e4a119eace8607c790a3c621f639477c","cik":1158895,"ticker":"LMAT","company_name":"LEMAITRE VASCULAR INC","filed_at":"2026-06-04T23:41:10+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"7,415","votes_against":"108,474","votes_for":"21,220,412","votes_withheld":null}]},"claim":"LEMAITRE VASCULAR INC shareholders approved Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2026 at the 2026-06-02 meeting.","evidence_excerpt":"the stockholders ratified the selection of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 with a vote of 21,220,412 shares for and 108,474 shares against, with 7,415 shares abstaining.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-257978","anchor_url":"https://secwatch.observer/filing/0001193125-26-257978#claim-7d0ae3e8e4a119eace8607c790a3c621f639477c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1158895/000119312526257978/0001193125-26-257978-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b85a0a3ac6c1369a5cf3946c364caab350a0f63f","cik":1158895,"ticker":"LMAT","company_name":"LEMAITRE VASCULAR INC","filed_at":"2026-06-04T23:41:10+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Advisory vote on the compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"1,197,877","subject":null,"votes_abstain":"13,559","votes_against":"813,052","votes_for":"19,311,813","votes_withheld":null}]},"claim":"LEMAITRE VASCULAR INC shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-02 meeting.","evidence_excerpt":"the stockholders approved, on an advisory basis, the Company's executive compensation by a vote of 19,311,813 shares for and 813,052 shares against, with 13,559 shares abstaining and 1,197,877 broker non-votes.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-257978","anchor_url":"https://secwatch.observer/filing/0001193125-26-257978#claim-b85a0a3ac6c1369a5cf3946c364caab350a0f63f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1158895/000119312526257978/0001193125-26-257978-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4f46a7da0bb9e75698730e823a1805208f8328ab","cik":1158895,"ticker":"LMAT","company_name":"LEMAITRE VASCULAR INC","filed_at":"2026-06-04T23:41:10+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Election of two Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"1,197,877","subject":"David B. Roberts","votes_abstain":null,"votes_against":null,"votes_for":"18,888,412","votes_withheld":"1,250,012"},{"broker_non_votes":"1,197,877","subject":"John A. Roush","votes_abstain":null,"votes_against":null,"votes_for":"14,229,071","votes_withheld":"5,909,353"}]},"claim":"LEMAITRE VASCULAR INC shareholders approved Election of two Class II directors at the 2026-06-02 meeting.","evidence_excerpt":"David B. Roberts received a vote of 18,888,412 shares for, 1,250,012 shares withheld and 1,197,877 broker non-votes. John A. Roush received a vote of 14,229,071 shares for, 5,909,353 shares withheld and 1,197,877 broker non-votes.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-257978","anchor_url":"https://secwatch.observer/filing/0001193125-26-257978#claim-4f46a7da0bb9e75698730e823a1805208f8328ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1158895/000119312526257978/0001193125-26-257978-index.htm"},{"fact_type":"earnings_release","fact_key":"18b35d6c4513f555ea14b7ef317f17e8fb286c74","cik":1158895,"ticker":"LMAT","company_name":"LEMAITRE VASCULAR INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"$0.79 - $0.84 (Mid $0.81, +35%.)","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Q2 2026","report_date":"2026-05-05","result_type":"guidance_update","revenue_text":"$70.5mm - $72.5mm (Mid $71.5mm, +11%, +11% org.)"},"claim":"LEMAITRE VASCULAR INC reported Q2 2026 results: revenue $70.5mm - $72.5mm (Mid $71.5mm, +11%, +11% org.), EPS $0.79 - $0.84 (Mid $0.81, +35%.). Guidance raised.","evidence_excerpt":"Business Outlook Q2 2026 Guidance Full Year Guidance Sales $70.5mm - $72.5mm (Mid $71.5mm, +11%, +11% org.) $277mm - $283mm (Mid $280mm, +12%, +12% org.) Gross Margin 72.1% 72.3% Op. Income $20.8mm - $22.3mm (Mid $21.6mm, +34%) $77.6mm - $82.0mm (Mid $79.8mm, +18%, +24% adj.) Op. Margin (Mid) 30% 29% EPS $0.79 - $0.84 (Mid $0.81, +35%.) $2.93 - $3.08 (Mid $3.00, +19%, +26% adj.)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-206578","anchor_url":"https://secwatch.observer/filing/0001193125-26-206578#claim-18b35d6c4513f555ea14b7ef317f17e8fb286c74","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1158895/000119312526206578/0001193125-26-206578-index.htm"},{"fact_type":"earnings_release","fact_key":"f53febc1b2bffe65d2039bcc7def7b2fece6e669","cik":1158895,"ticker":"LMAT","company_name":"LEMAITRE VASCULAR INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"EPS $0.68","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Q1 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"Sales $66.6mm"},"claim":"LEMAITRE VASCULAR INC reported Q1 2026 results: revenue Sales $66.6mm, EPS EPS $0.68.","evidence_excerpt":"LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance. Q1 2026: • Sales $66.6mm, +11% (+10% organic) vs. Q1 2025 • Gross margin 72.7% (+350 bps) • Op. income $17.8mm (+41%) • Op. margin 27% • EPS $0.68 (+42%) • Cash up $8.1mm sequentially to $367.2mm","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-206578","anchor_url":"https://secwatch.observer/filing/0001193125-26-206578#claim-f53febc1b2bffe65d2039bcc7def7b2fece6e669","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1158895/000119312526206578/0001193125-26-206578-index.htm"},{"fact_type":"executive_change","fact_key":"ba266d5636","cik":1158895,"ticker":"LMAT","company_name":"LEMAITRE VASCULAR INC","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-10","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Dorian LeBlanc was appointed as Chief Financial Officer at LEMAITRE VASCULAR INC.","evidence_excerpt":"On February 7, 2025, LeMaitre Vascular, Inc. (the “Company”) agreed to terms with Dorian LeBlanc to become the Chief Financial Officer and principal financial officer of the Company, effective on March 10, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-003679","anchor_url":"https://secwatch.observer/filing/0001437749-25-003679#claim-ba266d5636","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774925003679/0001437749-25-003679-index.htm"},{"fact_type":"executive_change","fact_key":"ea67a5810d","cik":1158895,"ticker":"LMAT","company_name":"LEMAITRE VASCULAR INC","filed_at":"2024-08-26T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2025-03-07","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Joseph P. Pellegrino, Jr. departed as Chief Financial Officer at LEMAITRE VASCULAR INC.","evidence_excerpt":"On August 26, 2024, LeMaitre Vascular, Inc. (the “Company”), announced that Joseph P. Pellegrino, Jr. will retire as an employee of the company, including as Chief Financial Officer, effective as of March 7, 2025, following the anticipated filing of the 2024 Fiscal Year 10-K.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-24-027754","anchor_url":"https://secwatch.observer/filing/0001437749-24-027754#claim-ea67a5810d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774924027754/0001437749-24-027754-index.htm"},{"fact_type":"earnings_release","fact_key":"0441bd1db18b879bcffa14a56aeb7b9056385bc0","cik":1158895,"ticker":"LMAT","company_name":"LEMAITRE VASCULAR INC","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":"$0.44","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$9.9mm","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-02","result_type":"preliminary_results","revenue_text":"$53.5mm"},"claim":"LEMAITRE VASCULAR INC reported the quarter ended March 31, 2024 results: revenue $53.5mm, net income $9.9mm, EPS $0.44. Guidance reaffirmed.","evidence_excerpt":"LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results ● Sales $53.5mm, +14% (+11% organic) vs. Q1 2023 ● Gross margin 68.6%, +300 bps ● Op. income $11.9mm, +51% ● Op. margin 22% ● Net income $9.9mm, +64% ● Earnings per diluted share $0.44, +62%","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-014372","anchor_url":"https://secwatch.observer/filing/0001437749-24-014372#claim-0441bd1db18b879bcffa14a56aeb7b9056385bc0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774924014372/0001437749-24-014372-index.htm"},{"fact_type":"earnings_release","fact_key":"604deb2c62f3cd1f4424c74b108ce89bdbbf1de6","cik":1158895,"ticker":"LMAT","company_name":"LEMAITRE VASCULAR INC","filed_at":"2024-02-27T23:59:59+00:00","payload":{"eps_text":"$0.38","guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":"$8.5mm","period_text":"the quarter ended December 31, 2023","report_date":"2024-02-27","result_type":"preliminary_results","revenue_text":"$48.9mm"},"claim":"LEMAITRE VASCULAR INC reported the quarter ended December 31, 2023 results: revenue $48.9mm, net income $8.5mm, EPS $0.38. Guidance initiated.","evidence_excerpt":"of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results ● Sales $48.9mm, +19% (+14% organic) vs. Q4 2022 ● Gross margin 68.1%, +450 bps ● Op. income $10.2mm, +46% ● Op. margin 21% ● Net income $8.5mm, +50% ● Earnings per diluted share $0.38, +49% ●","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-24-005732","anchor_url":"https://secwatch.observer/filing/0001437749-24-005732#claim-604deb2c62f3cd1f4424c74b108ce89bdbbf1de6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774924005732/0001437749-24-005732-index.htm"}]}